ArticleLeukemia2019
Phase 1 first-in-human trial of the anti-CD37 antibody BI 836826 in relapsed/refractory chronic lymphocytic leukemia.
Stephan Stilgenbauer et al.PubMed ↗Publisher ↗
No numbers read from the abstract.
17 papers cite it
this papercites it